Twelves, C. (2002) Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. British Journal of Cancer, 87/10, pp. 1072-1078. (doi: 10.1038/sj.bjc.6600626)
Full text not currently available from Enlighten.
Abstract
This phase I was study conducted to establish the maximum tolerated dose, dose-limiting toxicity, and recommended dose of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Twenty-six patients were treated with cyclophosphamide (600 mg m-2, intravenous bolus) followed by docetaxel (60, 75 or 85 mg m-2, 1-h intravenous infusion) every 3 weeks. The maximum tolerated dose was docetaxel 85 mg m-2 with cyclophosphamide 600 mg m-2, the dose-limiting toxicity being febrile neutropenia. Grade 4 neutropenia was experienced by all patients, but was generally brief. Otherwise, the combination was well tolerated with few acute and no chronic non-haematological toxicities of grade 3/4. Activity was observed at all dose levels and disease sites, and the overall response rate was 42% (95% confidence interval 22–61%). The pharmacokinetics of docetaxel were not modified by cyclophosphamide coadministration. These findings establish a recommended dose of docetaxel 75 mg m-2 in combination with cyclophosphamide 600 mg m-2 every three weeks for phase II evaluation.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | UNSPECIFIED |
| Authors: | Twelves, C. |
| College/School: | College of Medical Veterinary and Life Sciences |
| Journal Name: | British Journal of Cancer |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details